Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis

References

• Aggarwal S, Cudkowicz M. ALS drug development: reflections from the past and a way forward. Neurotherapeutics. 2008;5:516–27.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Meininger V. How can we improve clinical trials in amyotrophic lateral sclerosis? Nat Rev Neurol. 2011;7:650–4.
   PubMed Web of Science ®Google Scholar
• Mathis S, Couratier P, Julian A, Corcia P, Le Masson G. Current view and perspectives in amyotrophic lateral sclerosis. Neural Regen Res. 2017;12:181–4.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, et al. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group Study S0342. J Clin Oncol. 2010;28:4747–54.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol. 2013;31:2152–9.
   PubMed Web of Science ®Google Scholar
• Yap C, Pettitt A, Billingham L. Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia. BMC Med Res Methodol. 2013;13:87.
   PubMed Web of Science ®Google Scholar
• Schoenfeld DA, Cudkowicz M. Design of phase II ALS clinical trials. Amyotroph Lateral Scler. 2008;9:16–23.
   PubMed Web of Science ®Google Scholar
• Puopolo M, Pocchiari M. Need to improve clinical trials in rare neurodegenerative disorders. Ann Ist Super Sanita. 2011;47:55–9.
   PubMed Web of Science ®Google Scholar
• Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313:1619–20.
   PubMed Web of Science ®Google Scholar
• Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006;66:660–3.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheung YK, Levin B, Andrews H, Doorish C, Macarthur RB, et al. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler. 2008;9:212–22.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:235–44.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al. A clinical trial of creatine in ALS. Neurology. 2004;63:1656–61.
   PubMed Web of Science ®Google Scholar
• Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, et al. Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler. 2008;9:266–72.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, et al. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology. 2005;64:1655–6.
   PubMed Web of Science ®Google Scholar
• Hersch SM, Schifitto G, Oakes D, Bredlau AL, Meyers CM, Nahin R, et al. The CREST-E study of creatine for Huntington disease: a randomized controlled trial. Neurology. 2017;89:594–601.
   PubMed Web of Science ®Google Scholar
• Brooks B, Sanajak M, Roelke K. Phase 2B randomized dose-ranging clinical trial of tamoxifen, a selective estrogen receptor modulator (SERM), in amyotrophic lateral sclerosis (ALS): sensitivity analyses of discordance between survival and functional outcomes with long-term follow-up. Amyotroph Lateral Scler. 2005;6:118.
   Web of Science ®Google Scholar
• Levin B. ALS issues in clinical trials. Statistical issues. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:43–5.
   PubMed Web of Science ®Google Scholar
• Andres PL, Allred MP, Stephens HE, Proffitt Bunnell M, Siener C, Macklin EA, et al. Fixed dynamometry is more sensitive than vital capacity or ALS rating scale. Muscle Nerve. 2017;56:710–5.
   PubMed Web of Science ®Google Scholar
• Andres PL, Skerry LM, Munsat TL, Thornell BJ, Szymonifka J, Schoenfeld DA, et al. Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2012;45:81–5.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Moore DH, Miller R. Improving efficiency of ALS Clinical Trials (12th International Symposium on ALS/MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2001(2):20.
   Google Scholar
• Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo ML, et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res. 1996;2:619–22.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Kormanik PA. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol. 1999;56:703–8.
   PubMed Web of Science ®Google Scholar
• Robins HI, Won M, Seiferheld WF, Schultz CJ, Choucair AK, Brachman DG, et al. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro-oncology. 2006;8:47–52.
   PubMed Web of Science ®Google Scholar
• Odia Y, Kreisl TN, Aregawi D, Innis EK, Fine HA. A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas. J Neurooncol. 2015;125:191–5.
   PubMed Web of Science ®Google Scholar
• Qureshi MM, Cudkowicz ME, Zhang H, Raynor E. Increased incidence of deep venous thrombosis in ALS. Neurology. 2007;68:76–7.
   PubMed Web of Science ®Google Scholar
• Elman LB, Siderowf A, Houseman G, Kelley M, McCluskey LF. Venous thrombosis in an ALS population over four years. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:246–9.
   PubMed Web of Science ®Google Scholar
• Gladman M, Dehaan M, Pinto H, Geerts W, Zinman L. Venous thromboembolism in amyotrophic lateral sclerosis: a prospective study. Neurology. 2014;82:1674–7.
   PubMed Web of Science ®Google Scholar
• Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53:437–45.
   PubMed Web of Science ®Google Scholar
• Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP, et al. PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology. 2014;82:850–7.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60:22–31.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology. 1996;47:S242–S250.
   PubMed Web of Science ®Google Scholar
• Atassi N, Yerramilli-Rao P, Szymonifka J, Yu H, Kearney M, Grasso D, et al. Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology. 2013;81:1350–5.
   PubMed Web of Science ®Google Scholar
• Cheung YK, Gordon PH, Levin B. Selecting promising ALS therapies in clinical trials. Neurology. 2006;67:1748–51.
   PubMed Web of Science ®Google Scholar
• Swash M. Learning from failed trials in ALS. Lancet Neurol. 2007;6:1034–5.
   PubMed Web of Science ®Google Scholar